Urgent.News

What's breaking now, across thousands of outlets.

More in Health & Medicine

[Insight] Celltrion Expands Omlyclo 300mg Across Europe, Turning First-Mover Lead Into Tender Advantage

Celltrion is expanding the 300mg formulation of its omalizumab biosimilar Omlyclo across major European markets, a move that could help the South Korean biopharmaceutical company convert its…

  • Celltrion expands 300mg Omlyclo biosimilar to Germany, UK, France
  • European Commission approved 300mg formulation in November 2025
  • Strategy focuses on converting early lead into prescriptions and tender wins

More from Tuesday 25 August →